The Summit will move to Latin America in November 2017 - mark your calendar now!

UICC Members are invited to host the leading conference on knowledge transfer in cancer control, and raise their country and region profile amongst the global cancer and health community.

A quick reminder that the exclusive registration offer at €300 will end this week, on Friday 15 January...and the tickets for Paris have started moving fast

 

The CEO of Cancer Research UK and UICC Board member was knighted for his "hugely influential" work on prevention and treatment of cancer

The global cancer community once again has affirmed its commitment to excellence with a top quality preliminary programme of advanced topics.

New Website launched for the World Cancer Day 2016-2018 campaign

When opportunity knocks: learn how to advocate at local, national and European levels

UHC Day

700+ organisations in 116 countries say Universal Health Coverage is right, smart and overdue. Global leaders urged to ensure all people can access essential health services without facing financial hardship.

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

Boost your skills and learn from the best at the 2016 World Cancer Congress for only €300 instead of €620

Subscribe to